Ptc Therapeutics (PTCT) Capital Expenditures (2012 - 2026)

Ptc Therapeutics' Capital Expenditures history runs 15 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 30.57% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was -$401000.0, a 94.86% increase from a year earlier, with the FY2025 full-year figure at $126000.0, up 80.0% from the prior year.
• Capital Expenditures rose to $1.2 million in Q1 2026 per PTCT's latest filing, from -$6.4 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $16.5 million in Q2 2023 and bottomed at -$23.1 million in Q4 2022.
• The 5-year median for Capital Expenditures is $1.7 million (2025), against an average of $1.8 million.
• Across the five-year window, Capital Expenditures sank 364.57% in 2022 and surged 34142.86% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at -$23.1 million in 2022, then jumped by 124.11% to $5.6 million in 2023, then tumbled by 147.88% to -$2.7 million in 2024, then slumped by 138.65% to -$6.4 million in 2025, then soared by 118.82% to $1.2 million in 2026.
• Per Business Quant, the three latest PTCT Capital Expenditures figures stand at $1.2 million (Q1 2026), -$6.4 million (Q4 2025), and $3.4 million (Q3 2025).